Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
Sho Saeki, Junji Kishimoto, Daijiro Harada, Masafumi Yamaguchi et al.
Citations
2 citations
Journal
International Journal of Clinical Oncology
Topics
Lung Cancer Treatments and Mutations
Field-Weighted Citation Impact (FWCI)
3.04
article
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
International Journal of Clinical OncologyVol. 30(3)
Institutions
Kyushu University (JP), Oita University (JP), Kawasaki Medical School (JP), National Hospital Organization Kyushu Cancer Center (JP), Kyushu University Hospital (JP), Okayama University Hospital (JP), SAGA Heavy Ion Medical Accelerator in Tosu (JP), Okayama Red Cross General Hospital (JP), Chugoku Central Hospital (JP), Kumamoto University Hospital (JP), Kitakyushu Municipal Medical Center (JP), Shikoku Cancer Center (JP), Ehime Prefectural Central Hospital (JP)